周五，热景生物股价20CM涨停，股价创下历史新高，最新总市值为180.6亿元。 自去年9月18日以来，热景生物股价累计涨超724.8%，最低触及22.94元/股，最高达194.81元/股。 | → 分时 ■ 周 月 季 年 1分 5分 15分 30分 60分 30s ▼ 多周期 设置 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 日线(复权) 热景生物 MA5: 160.15↑ MA10: 149.86↑ MA20: 148.87↑ MA30: 141.63↑ MA60: 129.14↑ | | | | | | | | 《 个股K线区间统计 | | | X | | | | | | | | | 起始时间: 2024-09-18 | | | 周期个数: | | | | | | | | | 终止时间: 2025-07-04 | | | 191个 | | | | | | | | | 起始价: | 23.62 | 终止价: | 194.81 | | | | | | | ...

Core Viewpoint - The second largest shareholder of Hotgen Biotech, Zhou Xin, plans to reduce his stake in the company after a significant increase in stock price, indicating potential liquidity needs and market volatility [2][5]. Shareholder Actions - Zhou Xin intends to sell up to 1.8 million shares, representing approximately 1.94% of the total share capital, to meet personal funding requirements [2]. - As of the announcement date, Zhou Xin holds 6.8066 million shares, accounting for 7.342% of the total shares [3]. Financial Performance - In 2024, Hotgen Biotech reported a revenue of 511 million yuan, a year-on-year decrease of 6.74%, and a net loss of 191 million yuan, a significant decline of 760.4% [7]. - The company experienced a surge in performance during the COVID-19 pandemic in 2021, but both revenue and stock price have since declined sharply [6]. Historical Cashing Out - Prior to the current planned reduction, Zhou Xin has already cashed out approximately 2.1 billion yuan from his holdings in Hotgen Biotech since its IPO [4]. - His previous cashing out included approximately 21.59 million yuan in 2017 and 65.59 million yuan in 2018, totaling around 87.17 million yuan over those two years [4]. Market Context - Hotgen Biotech's stock price has seen a dramatic increase of over 6 times since late September 2024, similar to a previous surge of 5 times in April 2021 [5]. - As of June 25, 2024, the stock closed at 137.2 yuan per share, giving the company a market capitalization of 12.7 billion yuan [11]. Strategic Developments - The company is focusing on innovative biopharmaceutical technologies through its "Future Technology Research Institute," with strategic investments in companies developing cutting-edge antibody and nucleic acid drugs [11].

【导读】热景生物第二大股东拟减持不超过180万股公司股份 中国基金报记者 卢鸰 在股价暴涨超6倍后，热景生物第二大股东周锌又要减持。此前，在周锌于2021年7月减持前，热景生物股价在 当年 4月曾 一 月暴涨5 倍。 据热景生物6月25日晚公告，公司近日收到股东周锌发出的《关于减持公司股份的告知函》。因自身资金需求，股东周锌计划通过集中竞 价、大宗交易方式减持所持公司股份合计不超过180万股，占公司总股本的1.9416%。 以热景生物6月25日的收盘价估算，此次减持周锌将最 多 套现约2.5亿元。 总计 已 套现约2.1亿元 2019年9月热景生物在科创板上市时，周锌所持股份占比为10.35%，是公司第二大股东。 截至公告披露日，周锌仍为热景生物第二大股东，持有公司股份680.66万股，占公司股份总数的7.342% 。其 股份来源于公司首次公开发 行前持有及资本公积转增股本取得，已上市流通。 据招股书披露，通过协议转让方式，在上市前的2017年，周锌曾套现约2158.89万元，2018年又套现约6558.82万元，两年总计套现约 8717.71万元。 根据Wind数据，上市之后，通过二级市场，周锌已减持套现约 ...

5月22日，热景生物（688068.SH）召开2024年年度股东大会，根据上交所信息披露，会议就董事及高管薪酬议案、2024年 度财务决算报告、利润分配预案等进行了表决。 就在股东大会召开的前两天，北京热景生物发布关于股东权益变动触及1%刻度的提示性公告，公司的控股股东/实控人的一 致行动人青岛同程热景企业管理咨询合伙企业（有限合伙）（简称"青岛同程"）于2025年5月16日通过集中竞价减持，股东 权益合计比例从28.00%减少到26.99%，本次权益变动属于股东减持股份，不触及要约收购。 股价与业绩背离 有投资者称，这是一家靠卖试剂撑起新药研发的公司。该公司利用入股创新药企的做法，迎来了一波行情。曲线图显示， 热景生物股价从2024年最低点的22.94元/股，一路狂飙，今年还一度高达142元/股，暴涨了550%，股价实现了超五倍的增 长。让投资者意外的是，在IVD行业节节败退的当下，热景生物业绩下滑，股价却因为参股创新药概念而大涨，其动态市 盈率一度远超万孚生物、九安医疗等IVD同行。 具体来看，热景生物的重要战略参股公司舜景医药聚焦原始创新 FIC（First-In-Class）抗体药物的研发，其开发的 ...